T1D_Exchange_LOGO

Quality
Improvement
Collaborative

Learning Sessions

Archived Interventions

IMPROVAID, Type 1 Diabetes Screening and Monitoring, COVID-19,

IMPROVAID

Project Resources

Meeting Minutes

IMPROVAID Closeout Meeting February 12, 2026
IMPROVAID Monthly Check-in January 8, 2026
IMPROVAID Monthly Check-in December 11, 2025
IMPROVAID Monthly Check-in November 20, 2025
IMPROVAID Monthly Check-in October 9, 2025
IMPROVAID Monthly Check-in September 11, 2025
IMPROVAID Monthly Check-in Meeting Minutes August 14, 2025
IMPROVAID Monthly Check-in Meeting Minutes July 10, 2025
IMPROVAID Monthly Check-in Meeting Minutes June 12, 2026
IMPROVAID Monthly Check-in Meeting Minutes May 8, 2025
IMPROVAID Monthly Check-in Meeting Minutes April 10, 2025
IMPROVAID Monthly Check-in Meeting Minutes March 13, 2025
IMPROVAID Kickoff Meeting

Type 1 Diabetes Screening and Monitoring

T1DX Team Members

Nicole Rioles [nrioles@t1dexchange.org] – billing and contracts

Ann Mungmode [amungmode@t1dexchange.org] – quality improvement tools or process

Don Buckingham [dbuckingham@t1dexchange.org] – quality improvement tools or process

Emma Ospelt [eospelt@t1dexchange.org] – Smartsheet reporting and qualitative/quantitative analysis

Meeting Minutes

T1D Monitoring Project Meeting Minutes 4/26/2024
T1D Monitoring Project Meeting Minutes 3/22/2024
T1D Monitoring Project Meeting Minutes 2/6/2024

Center Tools

UF and Rady combined Fishbone diagram 2024.3.20 UF Process Map (TrialNet) 2023.9.25 Rady Process Map 2023.9.25 Rady Process Map 2024.4.26 T1DX-QI RAIL Template T1D Screening and Monitoring Qualtrics Survey Failure Mode and Effect Analysis draft 4/26/2024

Data

UF Screening Report 9.25.23

Resources

Rady T1D Screening Flyer (page 2) 2024.3.22 Rady T1D Screening Flyer (Page 1) 2024.3.22 Quinn et al - General Population Screening

COVID-19 Publications

Adoption of Telemedicine for Type 1 Diabetes Care During the COVID-19 Pandemic
Diabetes Technology Use for Management of Type 1 Diabetes Is Associated With Fewer Adverse COVID-19 Outcomes: Findings From the T1D Exchange COVID-19 Surveillance Registry
Diabetic ketoacidosis drives COVID-19 related hospitalizations in children with type 1 diabetes

Inequities in Diabetic Ketoacidosis Among Patients With Type 1

Diabetes and COVID-19: Data From 52 US Clinical Centers

Comment on Gregory et al. COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic’s Impact in Type 1 and Type 2 Diabetes.

General

Protocol Exemption Determination Letter Sample Survey Clinic Responses

Meeting Presentations

March 26th, 2021 Meeting

IRB

IRB Approval Letter IRB Example

Data Summaries

April 22, 2020 April 29, 2020 May 8, 2020

Need assistance or have a suggestion?

Reach the QI team directly and we'll route your request to the right person.

Contact Support

© 2026 T1D Exchange. All rights reserved.